- Home
- INDO vs ALXO Comparison
INDO vs ALXO Comparison
Compare INDO & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INDO | ALXO |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Indonesia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.1M | 68.3M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INDO | ALXO |
|---|---|---|
| Price | $4.62 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.42 |
| AVG Volume (30 Days) | ★ 3.5M | 872.5K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.21 | $0.41 |
| 52 Week High | $8.50 | $2.66 |
Technical Indicators
Market Signals| Indicator | INDO | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 51.04 |
| Support Level | $2.77 | $2.01 |
| Resistance Level | $5.12 | $2.27 |
| Average True Range (ATR) | 0.98 | 0.23 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 12.98 | 19.23 |
Price Performance
Historical ComparisonAbout INDO Indonesia Energy Corporation Limited
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. The company is an independent energy company engaged in the oil and gas business and holds two oil and gas assets through its subsidiaries in Indonesia: The Kruh Block and the Citarum Block. It has also identified a potential third exploration block known as the Rangkas area. . Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.